Disitamab Vedotin
HER2 Positive Breast Carcinoma
Explore 176 assets in HER2 Positive Breast Carcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fudan University
Modality
antibody_drug_conjugate
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07366840CT.gov RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure | — | Not Yet Recruiting | — | — | — |
NCT06157892CT.gov A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | — | Recruiting | — | — | — |
NCT07065435CT.gov RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | — | Recruiting | — | — | — |
NCT06278870CT.gov Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | — | Recruiting | — | — | — |
NCT05661357CT.gov Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression | — | Unknown | — | — | — |
NCT05649163CT.gov Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | — | Unknown | — | — | — |
NCT05135715CT.gov A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | — | Unknown | — | — | — |
NCT05134519CT.gov RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT04802876CT.gov Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | — | Active Not Recruiting | — | — | — |
NCT03500380CT.gov A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HER2 Positive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Disitamab Vedotin (this asset) | Fudan University | Approved | BB · 64 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Trastuzumab | SWOG Cancer Research Network | P4 | BB |
| Ribociclib | Danish Breast Cancer Cooperative Group | P3 | BB |
| Docetaxel | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Vinorelbine Ditartrate | Fudan University | P3 | BB |
| Cyclophosphamide | National University Hospital, Singapore | P3 | BB |
| Capecitabine | MedSIR | P4 | BB |
| Alpelisib | Criterium, Inc. | P3 | BB |
+42 more in the HER2 Positive Breast Carcinoma cohort
Other indications for Disitamab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastroesophageal Junction Adenocarcinoma | — | P2 | BB · 67 |
| Colorectal Cancer | — | P4 | B · 61 |
| Breast Cancer | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Disitamab Vedotin in HER2 Positive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/disitamab-vedotin-her2-positive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →